Biomarkers of Oral Cancer Discovered
|
By LabMedica International staff writers Posted on 30 Apr 2019 |

Image: A histopathology of oral cancer: tumor islands can be seen infiltrating the connective tissues deep to the overlying oral epithelium. This carcinoma is moderately differentiated with a non-cohesive invasive pattern (Photo courtesy of University of Sheffield).
Epigenetics, the non-genetic influences on gene expression, is a powerful mechanism capable of altering gene expression in cancer cells without changes to the DNA sequence, and can cause tumor progression.
Oral cancer is known for its high mortality rate in developing countries, but an international team of scientists hope its latest discovery will change that. The team has discovered epigenetic markers that are distinctly different in oral cancer tissues compared to the adjacent healthy tissues in patients.
Collaborating scientists from the University of Otago (Otago, New Zealand) and the Indian Statistical Institute (ISI, Kolkata, India) recruited 16 oral cancer patients in India, who were either tobacco smokers or chewers or of mixed habits, and took samples of both tumor and normal, adjacent tissue from them.
The team isolating the DNA in the samples, and discovered regions with altered epigenetic profiles in tumors cells compared to normal cells. They looked at one epigenetic mechanism, DNA methylation, which refers to the addition of methyl groups to DNA, like bookmarks. A total of 4,310 unique differentially methylated regions, mapping to 144 miRNA loci, were identified. Three distinct groups of miRNAs were differentially methylated in cancer tissues from smokers, chewers and mixed habitués. Hypermethylation of miR-503, miR-200a/b, miR-320b and miR-489 was associated with worse 5-year survival.
How these bookmarks are arranged could dictate the expression of genes and the spread of abnormal cells. Late diagnosis and poor prognosis are key problems associated with the high mortality rate of this cancer in developing countries. Of the 300,000 cases of tobacco associated oral cancer detected globally, 86% are from India. Aniruddha Chatterjee, PhD, a senior research fellow and co-author of the study, said, “This phenomenon is relatively new and under studied, particularly in oral cancer. This study is one of the first to identify epigenetic markers in oral cancer, using cutting-edge approaches.”
Roshni Roy, PhD, the lead author of the study, added, “We were also surprised to see that small molecules, called microRNA, were methylated or demethylated in the tumors from smokers or chewers or mixed habitués, suggesting that therapeutic intervention might be different in patients depending on the way the tobacco was abused.” The study was published on March 15, 2019, in the journal Epigenomics.
Related Links:
University of Otago
Indian Statistical Institute
Oral cancer is known for its high mortality rate in developing countries, but an international team of scientists hope its latest discovery will change that. The team has discovered epigenetic markers that are distinctly different in oral cancer tissues compared to the adjacent healthy tissues in patients.
Collaborating scientists from the University of Otago (Otago, New Zealand) and the Indian Statistical Institute (ISI, Kolkata, India) recruited 16 oral cancer patients in India, who were either tobacco smokers or chewers or of mixed habits, and took samples of both tumor and normal, adjacent tissue from them.
The team isolating the DNA in the samples, and discovered regions with altered epigenetic profiles in tumors cells compared to normal cells. They looked at one epigenetic mechanism, DNA methylation, which refers to the addition of methyl groups to DNA, like bookmarks. A total of 4,310 unique differentially methylated regions, mapping to 144 miRNA loci, were identified. Three distinct groups of miRNAs were differentially methylated in cancer tissues from smokers, chewers and mixed habitués. Hypermethylation of miR-503, miR-200a/b, miR-320b and miR-489 was associated with worse 5-year survival.
How these bookmarks are arranged could dictate the expression of genes and the spread of abnormal cells. Late diagnosis and poor prognosis are key problems associated with the high mortality rate of this cancer in developing countries. Of the 300,000 cases of tobacco associated oral cancer detected globally, 86% are from India. Aniruddha Chatterjee, PhD, a senior research fellow and co-author of the study, said, “This phenomenon is relatively new and under studied, particularly in oral cancer. This study is one of the first to identify epigenetic markers in oral cancer, using cutting-edge approaches.”
Roshni Roy, PhD, the lead author of the study, added, “We were also surprised to see that small molecules, called microRNA, were methylated or demethylated in the tumors from smokers or chewers or mixed habitués, suggesting that therapeutic intervention might be different in patients depending on the way the tobacco was abused.” The study was published on March 15, 2019, in the journal Epigenomics.
Related Links:
University of Otago
Indian Statistical Institute
Latest Pathology News
- AI Bone Marrow Mapping Provides New Tool to Track Blood Cancer Severity
- Digital Pathology Tool Predicts Breast Cancer Outcomes and Therapy Response
- AI Tissue Imaging Helps Guide Targeted Therapy for Lung Cancer
- Imaging Platform Maps Lipid Accumulations in Fabry Heart Tissue
- Tissue-Based Gene Signature Signals Colorectal Cancer Recurrence Risk
- FDA-Approved Companion Diagnostic Detects PTEN Loss in Prostate Cancer
- New AI Test Delivers Rapid Breast Cancer Recurrence Predictions
- EBV Status Helps Predict Survival in Primary CNS Lymphoma
- AI Pathology Tool Predicts Immunotherapy Response in Rare Cancers
- Uncertainty-Aware AI Tool Improves Digital Pathology for Cancer Subtyping
- Study Highlights Biomarker Testing Delays in Lung Cancer Care
- Stain-Free Imaging Platform Matches Standard Cancer Pathology
- New Companion Diagnostic Expands Precision Medicine in Prostate Cancer
- Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
- AI Tool Speeds Brain Tumor Classification from Routine Histology Slides
- IHC Companion Diagnostic Standardizes Mismatch Repair Testing for Cancer Immunotherapy
Channels
Clinical Chemistry
view channel
New Machine-Learning Equation Improves LDL Cholesterol Assessment
Accurate assessment of low-density lipoprotein (LDL) cholesterol is central to cardiovascular risk management, yet calculation methods can underestimate values in some patients. Laboratories widely use... Read more
Blood Biomarker May Signal Cognitive Decline Risk a Decade Before Symptoms
Accurately identifying which cognitively healthy older adults will later develop impairment due to Alzheimer’s disease remains difficult, as brain scans and genetic testing provide only part of the risk picture.... Read moreHematology
view channel
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
Treatment selection for hematologic malignancies often requires clinicians to synthesize clinical histories, genomic alterations, prior therapies, and rapidly evolving drug options. These complex decisions... Read moreImmunology
view channel
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
U.S. health authorities have reported a rapid increase in cyclosporiasis since May 2026, with more than 1,600 confirmed infections and thousands of additional suspected cases under investigation.... Read more
Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance mechanisms to guide effective therapy. Delays in profiling gram-negative organisms, which are frequently associated... Read morePathology
view channel
Digital Pathology Tool Predicts Breast Cancer Outcomes and Therapy Response
Breast cancer prognosis often depends on microscopic assessment of tumor architecture, a process that can be subjective and lead to variable predictions across patient groups. Quantitative measures that... Read more
AI Bone Marrow Mapping Provides New Tool to Track Blood Cancer Severity
Myelodysplastic neoplasms, a group of blood cancers that primarily affect older adults, are challenging to stage and monitor, often requiring repeated bone marrow biopsies that can yield uncertain interpretations.... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Bruker Expands NGS Capabilities for Sepsis and Bloodstream Infections
Bruker Corporation has acquired the DISQVER clinical metagenomics platform from Noscendo GmbH, expanding its next-generation sequencing infection detection portfolio. Following the acquisition, DISQVER... Read more








